Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > REGULATORY
REGULATORY
- Japan to Cap COVID Vaccine Copay at 7,000 Yen under NIP
March 18, 2024
- Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
March 18, 2024
- Another Daiichi Sankyo Veteran to Take Over as Provost of SCARDA
March 15, 2024
- Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
- Japan to Set Value-Based Share of 65% as Secondary Target for Generic Use
March 15, 2024
- Xocova Set for Renewed Price-Setting after Full Approval, Big Cut Unlikely
March 14, 2024
- PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
March 14, 2024
- CellCept, Paraplatin Now Eligible for Health Coverage
March 14, 2024
- LEO Pharma’s Eczema Drug Adtralza OK’ed for Self-Injection
March 14, 2024
- Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment
March 14, 2024
- Disclosure Guidelines on Generic Supply Info Up for Public Comments
March 13, 2024
- Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief
March 13, 2024
- English Versions of MHLW Biosimilar Trial Guidance, Q&As Now Available
March 13, 2024
- Japan to Simplify Screening for Third-Party Use of Highly Anonymous NDB Data
March 11, 2024
- Consolidate IRBs to Streamline Clinical Trials in Japan: Govt Working Group
March 11, 2024
- Japanese Health Minister Cautions Public on Multiple Measles Outbreaks
March 11, 2024
- PMDA Looks to Rev Up Pediatric and Orphan Drug Initiatives in Next 5-Year Plan: Chief
March 11, 2024
- MHLW Urges Distribution at Fair Price for Unprofitable Products
March 8, 2024
- New Govt Forum to Compile Interim Report to Create Innovation Ecosystem
March 8, 2024
- COVID Vaccine Labels to Be Updated with Booster Use as Main Regimen
March 8, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…